BioSpace News Archive

The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

MagForce anticipates to initiate patient enrollment in this study in the coming months.

Ms. Turner will oversee all legal matters for the Company and will report to Sangamo’s chief executive officer.

Fourth quarter and full-year 2017 consolidated revenue was $78.2 million and $306.6 million, an increase of 8% and 13%, respectively, compared to the fourth quarter and full-year 2016.

Invitae today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.

Brad Mason, Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 4:30 p.m. ET the same day.

Management will host a conference call at 4:30 p.m. Eastern Time on March 12 to discuss the results of the quarter and fiscal year and to host a question and answer session.

Kadmon today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.